Skip to main content

EDITORIAL article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1449566
This article is part of the Research Topic Advances in the Treatment of Hormonal Receptor positive (HR+) Breast Cancer View all 12 articles

Advances in the Treatment of Hormonal Receptor positive (HR+) Breast Cancer

Provisionally accepted
Wala BEN KRIDIS Wala BEN KRIDIS 1*Zheng Wang Zheng Wang 2Deniz Can Guven Deniz Can Guven 3Arunasalam Dharmarajan Arunasalam Dharmarajan 4
  • 1 Habib Bourguiba University Hospital, Sfax, Tunisia
  • 2 Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Beijing, China
  • 3 Atatürk Institute, Hacettepe University, Ankara, Ankara, Türkiye
  • 4 Medical Centre, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India

The final, formatted version of the article will be published soon.

    Keywords: breast cancer, CDK 4/6 inhibitors, PIK3CA, Genetics, aromatase inhibiters, Toxicity

    Received: 15 Jun 2024; Accepted: 06 Sep 2024.

    Copyright: © 2024 BEN KRIDIS, Wang, Guven and Dharmarajan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wala BEN KRIDIS, Habib Bourguiba University Hospital, Sfax, Tunisia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.